文献速递临床试验与 GCP流行病学与生物统计

锌预防镰状细胞贫血感染(ZIPS):乌干达镰状细胞贫血儿童随机安慰剂对照试验研究方案

Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia.
PubMed 文献 · Trials · 2019-07-26

ZIPS 是一项在乌干达开展的随机、安慰剂对照、双盲临床试验,计划纳入 250 名 1.00–4.99 岁镰状细胞贫血(SCA)儿童,每日补充锌(10 mg 口服分散片)或相同安慰剂,持续 12 个月,旨在评估锌对严重或侵袭性感染发病率的影响。背景指出 SCA 儿童感染负担重,锌缺乏导致免疫受损和感染风险增加,但 5 岁以下 SCA 儿童补锌预防感染的有效性尚无数据。

要点

  • ZIPS 试验在乌干达 1.00–4.99 岁 SCA 儿童中比较每日 10 mg 锌口服分散片与安慰剂,疗程 12 个月。
  • 主要目标是评估补锌能否降低严重或侵袭性感染发病率,目前 5 岁以下 SCA 儿童无此类数据。
  • 若试验显示感染减少,将作为在非洲 SCA 儿童中开展多中心、多国家临床试验评估锌真实世界安全性和有效性的依据。

核心结论

  • 若该试验显示严重或侵袭性感染发病率降低,将成为在非洲 SCA 儿童中开展多中心、多国家临床试验以评估锌真实世界安全性和有效性的基础。
  • 锌安全、价廉且易于给药,该试验有望通过减少感染相关发病和死亡改善数十万非洲 SCA 儿童的健康。

研究设计与样本

  • 研究设计为随机、安慰剂对照、双盲临床试验,计划纳入 250 名乌干达 1.00–4.99 岁 SCA 儿童。
  • 干预为每日补充锌(10 mg 口服分散片)或相同安慰剂,持续 12 个月。
  • 试验注册于 Clinicaltrials.gov,注册号 NCT03528434,注册日期 2018 年 5 月 17 日;方案版本 1.0,日期 2017 年 12 月 11 日;申办方为印第安纳大学(Indiana University),申办方方案标识 1712339562。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文在背景中指出,目前尚无数据关于锌预防 5 岁以下 SCA 儿童感染的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sickle cell anemia (SCA) is the most common inherited hemoglobinopathy worldwide. Infection is a major cause of illness and death in children with SCA, especially in sub-Saharan Africa where an estimated 50-90% of affected children die before their fifth birthday. Interventions to reduce the incidence and severity of infections are needed urgently. A high proportion of adults and children with SCA are zinc-deficient, and zinc deficiency leads to impaired immunity and an increased risk of infection. Zinc supplementation has been shown to decrease the risk of infection in adolescents and adults, but there are no data on the effectiveness of zinc for prevention of infection in children < 5 years of age with SCA. METHODS/DESIGN: The study will be a randomized, placebo-controlled, double-blind clinical trial in which 250 Ugandan children 1.00-4.99 years of age with SCA will receive daily zinc supplementation (10 mg oral dispersible tablet) or identical placebo for 12 months. DISCUSSION: If this trial shows a reduction in severe or invasive infection incidence, it would be the basis for a multi-site, multi-country clinical trial to assess real-world safety and efficacy of zinc in African children with SCA. Since zinc is safe, inexpensive, and easy to administer, this trial has the potential to improve the health of hundreds of thousands of African children with SCA through reduction of infection-related morbidity and mortality. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03528434. Registered on May 17, 2018 Protocol Version: 1.0. Date: Dec 11, 2017 Sponsor: Indiana University. Sponsor's protocol identifier, 1712339562.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Datta D, Namazzi R, Conroy AL, et al. Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia. Trials. 2019. PMID: 31349866. doi:10.1186/s13063-019-3569-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。